Årsredovisning för 2022 publicerad | Iconovo

Investors
News
Contact

About us
Inhalers
- Inhalers
- ICOres
- ICOcap
- ICOpre
- ICOone
- ICOone Nasal
- Patents
Development services
Partner with us
- Partner with us
- Iconovo Accelerator Program
Insights
- Replacing injections with inhalation
- Boost your business with an innovative inhaler partner
Investors
Search
Menu Menu

LinkedIn

Iconovo AB (publ) har publicerat årsredovisning för 2022. Läs årsredovisningen här

Possessing a unique combination

of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.

ICONOVO AB

VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B

POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 70 LUND
Sweden

CONTACT

Phone: +46 46 275 67 77

VP Business Development
Roger Lassing
Mail: roger.lassing@iconovo.se

CEO
Johan Wäborg
Mail: johan.waborg@iconovo.se

SITEMAP

Home
Development services
Investors

Press releases

Follow us on Linkedin

Iconovo, Arcede Pharma AB and Lund University receive funding from Swelife to...

Study start for Monash University with inhaled oxytocin in ICOone